Post-Polio Syndrome (PPS)
What is Post-Polio Syndrome?
Polio, also known as poliomyelitis, is an acute infectious disease caused by poliovirus that seriously endangers children's health. Poliovirus is a neurotropic virus, which mainly impinges on motor nerve cells of the central nervous system and damages motor neurons of the anterior horn of the spinal cord. Patients are mostly 1-6 years old children, the main symptoms are fever, general discomfort, severe limb pain, irregular distribution, and severity of flaccid paralysis. Post-polio syndrome (PPS) is a rare disorder that mainly affects people who have been infected with polio that can lead to the dysfunction of the nerves and muscles. These PPS patients gradually experience fatigue, muscle and joints weakness. Several studies have suggested that PPS may be caused by reactivation of the virus, overregulation in nerve cells, or abnormal neural regeneration and differentiation in polio survivors.
Fig.1 Putative factors in the etiology of generalized fatigue in post-polio syndrome. (Li Hi Shing, 2019)
PPS Prevalence and Risk Factors
Recently, a wide variety of risk factors, such as aging, that are associated with PPS have been studied in different kinds of human populations. For example, recent reports have indicated that a close relationship between the frequency or severity of PPS disease and age. Moreover, many researchers have demonstrated that cigarette smoking and trauma have become the key risk factors of PPS. The results have shown that non-smoking and non-traumatic people are less likely to develop PPS. Meanwhile, people who have been vaccinated against polio are also less likely to get PPS. Besides, most middle-aged polio survivors are at high risk of PPS and deserve extensive attention and scientific management.
The PPS Treatment Options
Up to now, a battery of methods have been generated for the treatment of patients with PPS, including but not limited to:
- Physical therapy
- Drug Treatment
- Intravenous Immunoglobulin
The management of PPS is still based on rehabilitation training. In general, it includes lifestyle management, physical exercise, and personalized training. Exercise can increase muscle strength, improve muscle endurance and reduce fatigue. Training is designed by using alternating interval exercises to improve muscle function while ensuring adequate rest time. Furthermore, training in warm water reduces pain-killing muscles and reduces joint damage. Therefore, dynamic water sports are also a good alternative treatment for PPS patients.
Currently, many attempts have been made to identify new inflammatory markers in the serum and CSF from PPS patients. Pilot studies have found that these markers can be a candidate target for discovering novel drugs against PPS. Also, a series of pain relievers have been broadly used to ease muscle and joint pain in PPS patients. In addition, several corticosteroids have been developed and evaluated their efficacies in enhancing muscle strength and improving fatigue of PPS patients.
In the past few years of studies, intravenous immunoglobulin (IVIG) has proven its significant role in the treatment of neurological diseases and dysfunctions. IVIG is considered to have a positive effect on regulating CSF inflammatory cytokine levels in PPS patients. As a result, it has been considered as a potential treatment for PPS and can act via several mechanisms, including Fc-receptors regulation, B/T cells mediation, neutralization of pathogenic antibodies, as well as cytokine production. Among them, many products specific for Neural Proteins & Peptides and Neural Antibodies have been designed for PPS in pre-clinical trials.
Through our comprehensive neuroscience studies services, Creative Biolabs provides advanced technologies and protocols customized to suit any PPS project. We have experienced experts and advanced platforms that can provide excellent services. If you are interested in our services, please feel free to contact us.
Reference
- Li Hi Shing, S.; et al. Post-polio syndrome: more than just a lower motor neuron disease. Frontiers in neurology. 2019, 10: 773.
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1684) (Cat#: NRP-0422-P1684)
- NeuroMab™ Anti-TREM2 BBB Shuttle Antibody(NRZP-1022-ZP4114) (Cat#: NRZP-1022-ZP4114)
- NeuroMab™ Anti-FGFR1 Antibody(NRP-0422-P1244) (Cat#: NRP-0422-P1244)
- NeuroMab™ Anti-Integrin αvβ8 BBB Shuttle Antibody(NRZP-1222-ZP1218) (Cat#: NRZP-1222-ZP1218)
- NeuroMab™ Anti-TREM2 Antibody(NRP-0422-P792) (Cat#: NRP-0422-P792)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- NeuroMab™ Anti-CD20 Antibody(NRP-0422-P1230) (Cat#: NRP-0422-P1230)
- NeuroMab™ Anti-Amyloid Beta 1-15 Antibody(NRP-0422-P867) (Cat#: NRP-0422-P867)
- NeuroMab™ Anti-SEZ6 Antibody(NRP-0422-P517) (Cat#: NRP-0422-P517)
- Rat Glioma Cell Line C6 (Cat#: NCL2110P346)
- iNeu™ Human Sensory Neurons (Cat#: NCL-2103-P62)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Rat Schwann Cells RSC96, Immortalized (Cat#: NCL-2108P21)
- iNeu™ Human Motor Neurons (Cat#: NCL-2103-P71)
- Rat Muller Cell (Cat#: NCL2110P040)
- Human Neurons Isolated from Cortex (Cat#: NCL-21P6-023)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Rat Retinal Muller Cell Line, Immortalized (Cat#: NCL-21P6-192)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- pAAV-syn-jGCaMP8m-WPRE (Cat#: NTA-2106-P062)
- pAAV-syn-jGCaMP8f-WPRE (Cat#: NTA-2106-P061)
- pAAV-syn-FLEX-jGCaMP8f-WPRE (Cat#: NTA-2106-P064)
- Dextran-FITC (Cat#: NTA-2011-ZP110)
- pAAV-syn-FLEX-jGCaMP8m-WPRE (Cat#: NTA-2106-P065)
- pAAV-syn-jGCaMP8s-WPRE (Cat#: NTA-2106-P063)
- pAAV-hSyn-DIO-XCaMP-R-WPRE (Cat#: NTA-2012AD-P508)
- rAAV-E-SARE-Cre-ERT2-PEST-WPRE-hGH polyA (Cat#: NTA-2010-TT342)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Dextran, NHS Activated, 40 kDa (Cat#: NRZP-0722-ZP124)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)